Trial Profile
An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Generalised seizures; Partial epilepsies; Seizures
- Focus Adverse reactions
- Acronyms BRITE
- Sponsors UCB
- 01 Jan 2023 Results of post hoc analysis evaluating long-term retention, reasons for discontinuation, efficacy, tolerability, and health-related quality of life (HRQOL) during adjunctive brivaracetam (BRV) treatment in adults with focal seizures by number of lifetime antiseizure medications published in the Epilepsy and Behavior
- 01 May 2021 Results reporting efficacy outcomes up to 36 months published in the Epilepsy and Behavior
- 08 Dec 2020 Results of post hoc analysis evaluating the long-term retention, reasons for discontinuation, efficacy and tolerability of adjunctive brivaracetam (BRV) in adults with focal seizures by number of lifetime antiepileptic drugs (AEDs). presented at the 74th Annual Meeting of the American Epilepsy Society